Objectives: To explore the associations between vaccine hesitancy and demographic and socio-economic characteristics, as well as perspective towards the COVID-19 and its vaccines.
Methods: Data were collected through four online surveys on Israel's representative sample in March (3/2 to 3/7, n = 1517), August (8/10-8/11, n = 925; 8/18-8/22, n = 1054), and September (9/22-9/24; n=1406), 2021. We employ a set of logistic regression models to explore the association between the vaccination action and intentions and the individual-level attributes.
Results: We find that individual characteristics, such as age, ethnicity/religiosity, and income, were associated with the vaccination action and intention during the early stage of vaccine distribution. However, most of the discrepancies across demographic groups have disappeared as time passed, and once we limit to those who had not been infected. Lastly, individuals' perspectives toward COVID-19 and its vaccines have prediction power as high as 39% of the vaccination action and intention, higher than their demographic and socio-economic characteristics.
Implications: Our findings have the potential to facilitate efforts to increase vaccine uptake by targeting populations, which are the most likely to express hesitancy, and address reported barriers to receipt.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831127 | PMC |
| http://dx.doi.org/10.1016/j.vaccine.2022.02.031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Live Plague Vaccine Development: Past, Present, and Future.
Vaccines (Basel)
January 2025
Laboratory for Plague Microbiology, Especially Dangerous Infections Department, State Research Center for Applied Microbiology and Biotechnology, 142279 Obolensk, Russia.
During the last 100 years, vaccine development has evolved from an empirical approach to one of the more rational vaccine designs where the careful selection of antigens and adjuvants is key to the desired efficacy for challenging pathogens and/or challenging populations. To improve immunogenicity while maintaining a favorable reactogenicity and safety profile, modern vaccine design must consider factors beyond the choice of target antigen alone. With new vaccine technologies currently emerging, it will be possible to custom-design vaccines for optimal efficacy in groups of people with different responses to vaccination.
View Article and Find Full Text PDFSafety, Tolerability, and Immunogenicity of the Invaplex Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial.
Vaccines (Basel)
January 2025
Leiden University Center for Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Background: Shigella infections remain endemic in places with poor sanitation and are a leading cause of diarrheal mortality globally, as well as a major contributor to gut enteropathy and stunting. There are currently no licensed vaccines for shigellosis but it has been estimated that an effective vaccine could avert 590,000 deaths over a 20-year period. A challenge to effective Shigella vaccine development has been the low immunogenicity and protective efficacy of candidate Shigella vaccines in infants and young children.
View Article and Find Full Text PDFUsing Human-Centered Design to Bridge Zero-Dose Vaccine Gap: A Case Study of Ilala District in Tanzania.
Vaccines (Basel)
January 2025
Department of Preventive Services, Ministry of Health, Dodoma P.O. Box 743, Tanzania.
Immunization plays a substantial role in reducing the under-five mortality rate. However, Tanzania still has a significant number of zero-dose and under-vaccinated children and was ranked among the top ten African countries with the highest numbers of zero-dose children in 2022. The human-centered design (HCD) approach is more ethical and effective at addressing public health challenges in complex sociocultural settings.
View Article and Find Full Text PDFTranscriptional Systems Vaccinology Approaches for Vaccine Adjuvant Profiling.
Vaccines (Basel)
January 2025
Vaccine and Infectious Diseases Organization (VIDO), University of Saskatchewan, Saskatoon, SK S7N 5A2, Canada.
Adjuvants are a diverse group of substances that can be added to vaccines to enhance antigen-specific immune responses and improve vaccine efficacy. The first adjuvants, discovered almost a century ago, were soluble crystals of aluminium salts. Over the following decades, oil emulsions, vesicles, oligodeoxynucleotides, viral capsids, and other complex organic structures have been shown to have adjuvant potential.
View Article and Find Full Text PDFDecoding NAD+ Metabolism in COVID-19: Implications for Immune Modulation and Therapy.
Vaccines (Basel)
December 2024
Department of Respiratory, Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361101, China.
The persistent threat of COVID-19, particularly with the emergence of new variants, underscores the urgency for innovative therapeutic strategies beyond conventional antiviral treatments. Current immunotherapies, including IL-6/IL-6R monoclonal antibodies and JAK inhibitors, exhibit suboptimal efficacy, necessitating alternative approaches. Our review delves into the significance of NAD+ metabolism in COVID-19 pathology, marked by decreased NAD+ levels and upregulated NAD+-consuming enzymes such as CD38 and poly (ADP-ribose) polymerases (PARPs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!